E-viri
Recenzirano Odprti dostop
  • Changes in Ultrasound-Asses...
    Sala-Vila, Aleix; Romero-Mamani, Edwin-Saúl; Gilabert, Rosa; Núñez, Isabel; de la Torre, Rafael; Corella, Dolores; Ruiz-Gutiérrez, Valentina; López-Sabater, María-Carmen; Pintó, Xavier; Rekondo, Javier; Martínez-González, Miguel-Ángel; Estruch, Ramon; Ros, Emilio

    Arteriosclerosis, thrombosis, and vascular biology, 2014-February, 2014-Feb, 2014-02-00, 20140201, Letnik: 34, Številka: 2
    Journal Article

    OBJECTIVE—The Prevención con Dieta Mediterránea (PREDIMED) trial showed that a Mediterranean diet (MedDiet) supplemented with either extra virgin olive oil or 30 g/d of mixed nuts reduced incident cardiovascular events compared with a control (low fat) diet. The mechanisms of cardiovascular protection afforded by MedDiets remain to be uncovered. We assessed the effect of both supplemented MedDiets on internal carotid intima-media thickness (ICA-IMT) and plaque height, the ultrasound features that best predict future cardiovascular events, in subjects at high cardiovascular risk. APPROACH AND RESULTS—In a PREDIMED subcohort (n=175), plaque height and carotid IMT of 3 prespecified segments (ICA, bifurcation, and common) were sonographically assessed at baseline and after intervention for a mean of 2.4 years. We evaluated 164 subjects with complete data. In a multivariate model, mean ICA-IMT progressed in the control diet group (mean 95% confidence interval, 0.052 mm −0.014 to 0.118 mm), whereas it regressed in the MedDiet+nuts group (−0.084 mm −0.158 to −0.010 mm; P=0.024 versus control). Similar results were observed for maximum ICA-IMT (control, 0.188 mm 0.077 to 0.299 mm; MedDiet+nuts, −0.030 mm −0.153 to 0.093 mm; P=0.034) and maximum plaque height (control, 0.106 mm 0.001 to 0.210 mm; MedDiet+nuts, −0.091 mm −0.206 to 0.023 mm; P=0.047). There were no changes in ICA-IMT or plaque after the MedDiet+extra virgin olive oil. CONCLUSIONS—Compared with a control diet, consumption of a MedDiet supplemented with nuts is associated with delayed progression of ICA-IMT and plaque. The results contribute mechanistic evidence for the reduction of cardiovascular events observed in the PREDIMED trial. CLINICAL TRIAL REGISTRATION—URLhttp://www.controlled-trials.com. Unique identifierISRCTN35739639.